Research

Research Statement

We study the relationship between stress, aging and metabolism. Although generally considered promoters of aging due to damaged cellular architecture and accelerated metabolic dysregulation, stressors can induce an array of defense mechanisms that reduce damage and paradoxically suppress aging and age-related degenerative processes. We hope that, in the future, we are able to utilize some of these protective mechanisms to clinically extend life- and health-span. We have three specific research projects that cover the stress-aging relationship.

(1) Sestrin, a family of stress-inducible proteins that suppress age- and obesity-associated pathologies.

Sestrin was originally discovered as a target of the tumor suppressor p53 in a differential display screening. Follow-up studies have revealed that there are three Sestrin genes (Sestrin1-3) in the mammalian genome and that all three can be transcriptionally upregulated after a variety of environmental stress, including genotoxic, oxidative and hypoxic stresses. In cultured cells, Sestrins exhibit two important biological activities – suppression of reactive oxygen species (ROS) and inhibition of mammalian target of rapamycin complex 1 (mTORC1) signaling. Because excessive ROS accumulation and mTORC1 activation are well-known facilitators of aging and age-associated diseases, Sestrins are viewed as a potential linker between stress signaling and aging physiology. However, when we first started investigating this protein family, there was very limited information known on its physiological function, due to the absence of any genetic studies in model organisms. Furthermore, the molecular nature of Sestrin and biochemical mechanisms of how Sestrin inhibits ROS and mTORC1 were both unknown.

Subsequently, we were the first to generate Sestrin-deficient and Sestrin-overexpressing animal models using the Drosophila system, and to discover the role of Sestrins as a feedback inhibitor of mTORC1 signaling that attenuates various age- and obesity-associated metabolic pathologies (Lee et al. Science 327, 1213). This work was conducted in Dr. Michael Karin’s lab at UC San Diego, where the PI did his postdoctoral training. After moving to the University of Michigan, we continued following up with these findings using mouse models of obesity and diabetes. As a result, we were able to demonstrate that Sestrins regulate metabolism in the mammalian system. Specifically, we showed that Sestrin2 is induced in the liver upon obesity and subsequently attenuates obesity-induced hepatosteatosis and hepatic insulin resistance through regulation of the AMPK-mTORC1 pathway (Lee et al. Cell Metab, 16, 311).

We further investigated the mechanisms underlying how Sestrins regulate metabolism. We showed that Sestrin2 maintains liver ER homeostasis under conditions of obesity-associated lipotoxic challenges, and thereby attenuates the progression of fatty liver pathologies (Park et al. Nat Commun, 5, 4233). Biochemically, Sestrins regulate mTORC1 through the GATOR1/2 complexes (Kim et al. Sci Rep 5, 9502), two multi-protein complexes recently identified to regulate mTORC1. Sestrin2-GATOR2 interaction was also important for upregulation of mTORC2, which was independent of mTORC1 regulation (Kowalsky et al. J Biol Chem in press). Sestrin2 also directly regulates autophagy through ULK1, an autophagy-initiating protein kinase (Ro et al. FEBS J 281, 3816). At the structural level, Sestrin2 shows striking internal symmetry with two homologous domains: one domain is responsible for ROS reduction and the other associates with GATOR2 to modulate mTORC1 signaling (Kim et al. Nat Commun 6, 10025); the structural study was done in collaboration with Dr. Uhn-Soo Cho’s lab (UM – BioChem).

The Sestrin functions are not just important in liver, but also in other organs. In brown adipocytes, Sestrin2’s ROS-reducing activity was important for regulating mitochondrial thermogenesis through Ucp1 regulation (Ro et al., PNAS 111, 7849). In colon, Sestrin2 was important for maintaining epithelial homeostasis and suppressing growth of colon tumor cells; Sestrin2 was revealed to be one of the important tumor suppressors functioning downstream of p53 (Ro et al. eLife 5, e12204). In T cells, Sestrins suppress immune response upon aging (Lanna et al. Nat Immunol., 18, 354). In heart, Sestrins were also critical for protecting cardiomyocytes from ischemia-reperfusion injury (Morrison et al. FASEB 29, 408) and doxorubicin-induced cardiotoxicity (Li et al. Am J Physiol Heart Circ Physiol., 317, H39). These studies were conducted either in our lab or as a collaboration with Drs. Yatrik Shah (UM – MIP), Arne Akbar (UCL, UK), Ji Li (SUNY Buffalo) and Zunjian Zhang (China Pharmaceutical University).

Most importantly, our recent work, conducted with Dr. Robert J. Wessells' lab (Wayne State University), highlighted the critical role of Sestrins in mediating the benefits of physical movements and exercise. Using both fly and mouse systems, we showed that Sestrin deficiency can nullify exercise benefits in improving endurance performance and metabolic fitness (Kim et al. Nat Commun 11, 190). In contrast, Sestrin overexpression mimicked various effects of exercise. For instance, collaboration with Dr. Pura Muñoz Cánoves (UPF) demonstrated that Sestrin overexpression could be highly effective for preventing muscle loss during disuse and aging (Segalés et al. Nat Commun 11, 189). These results suggest that Sestrin mimetics or activators could be used as a novel way to treat age- or physical inactivity-related muscle wasting.

These series of research findings greatly enhanced our understanding of (1) the physiological functions of Sestrins in a mammalian model, (2) the biochemical basis of Sestrins’ physiological activities, and (3) the potential of Sestrin modulators and mimetics for attenuating or treating diverse metabolic disorders associated with aging and obesity. This progress, along with the advances made by others in the field, are summarized in recent review articles from our group (Lee et al. Cell Metab 18, 792; Ro et al. Front Endocrinol 6, 114; Ho et al. Trends Biochem Sci 41, 621).

Biochemical and Physiological Roles of Sestrins.

(Center) Janus-faced Sestrins reduce oxidative stress and suppress mTORC1 signalling through their two independent functional motifs that face diametrically opposed directions. (Upper) Many different environmental stress can regulate Sestrins through transcriptional and post-transcriptional mechanisms. (Left) Sestrins reduce oxidative stress through multiple independent mechanisms. (Right) Sestrins regulate multiple cell signaling pathways. (Lower) Through these activities, Sestrins suppress a variety of age- and obesity-associated pathologies.

(2) Molecular mechanisms underlying physiological autophagy regulation and pathogenetic mechanisms of how autophagy is abrogated in human diseases.

Autophagy is a physiological process that is responsible for the elimination of toxic protein aggregates, unnecessary nutrient deposits and dysfunctional organelles such as damaged mitochondria. Therefore, autophagy is important for resolving stress-induced damages, and defective autophagy is implicated in many human diseases such as metabolic abnormalities and neurodegeneration. Autophagy is also one of the important targets of the Sestrin-mTORC1 signaling pathway.

Using the Drosophila model system, we devised a novel screening method that can efficiently isolate new autophagy regulators. Using mutant flies for the Fip200 gene, a homolog of the mammalian Fip200/Rb1cc1 gene that controls autophagy, we have confirmed that this scheme is operational for isolating formerly unidentified genes (Kim et al. Autophagy 9, 1201). Among the autophagy-regulating candidate genes, we were intrigued by a gene named Gyf, which is a homologue of a human gene Gigyf2/PARK11, whose mutation was proposed to play a causative role in a familial type of Parkinson’s disease. Through extensive genetic analyses, we established that Gyf is an important regulator of autophagy that prevents neurodegenerative pathologies in flies (Kim et al., Autophagy 11, 1358). Strikingly, Gigyf2-deficient mice also exhibited neurodegenerative phenotypes, suggesting conservation of gene function across invertebrate and mammalian species.

While conducting these projects, we learned that Dr. Margit Burmeister in the Department of Human Genetics at the University of Michigan recently isolated a novel sequence variant (E122D) of the human ATG5 gene, from a family with ataxia patients. Dr. Daniel Klionsky’s lab initially characterized this mutation in yeast and found that the homologous mutation impaired the autophagy-regulating function of the yeast Atg5 gene. We further extended these findings and showed that (1) patient-derived cell lines had a strong impairment in the autophagy process, (2) the mutation interferes with conjugation between Atg5 and Atg12, a critical step in autophagy, and (3) WT, but not the E122D mutant, human ATG5 can rescue ataxia-like neurodegenerative phenotypes of Atg5-null mutant flies (generated by Dr. Gabor Juhasz group in Hungary). This is the first demonstration of a genetically-inherited human mutation in a core autophagy gene with a pathological implication (Kim et al. eLife 5:e12245).

We also investigated the pathogenetic mechanisms of how obesity compromises autophagy. Notably, it has been known that obesity and non-alcoholic steatohepatitis are associated with the accumulation of insoluble protein aggregates that are composed of ubiquitinated proteins and ubiquitin adaptor p62/sequestosome 1 (SQSTM1), which are normally substrates of autophagy. We showed that lipotoxic insults can chronically elevate cytoplasmic calcium levels, which specifically inhibits the fusion between autophagosomes and lysosomes. Correspondingly, inhibition of cytosolic calcium influx through calcium channel blockers restored autophagy and metabolic homeostasis in obese mice. This clarified the mechanism of how obesity inhibits autophagy and how we are able to normalize this dysregulation pharmacologically (Park et al. Nat Commun 5, 4834). In addition to the autophagic mechanism, we also found that lipotoxic activation of TBK1 and subsequent p62/SQSTM1 phosphorylation are critical steps in the NASH pathology of protein inclusion accumulation in hepatocytes (Cho et al. Hepatology 68, 1331). Such dysregulation of protein homeostasis could be similarly observed in a new model of liver failure, which was provoked by unregulated mTORC1 hyperactivation (Cho et al. Cell Discov. 5, 60).

The pathophysiological roles of autophagy in neuronal homeostasis (Kim et al. Int J Mol Sci. 18, E1596; Burmeister et al. Autophagy 12, 1208) and metabolic regulation (Cho et al. Hepatology 66, 700; Park and Lee, Autophagy 10, 2385; Namkoong et al. Mol Cells 41, 3), partially revealed by our studies described above, are summarized in our recent reviews and commentaries.

Relationship between Obesity and Autophagy

Sophisticated interaction between autophagy and obesity-associated pathologies is schematically illustrated. The image and text are from Mol Cells. 41, 3–10.

(3) Stress-induced alteration of the mRNA transcriptome at subcellular and single cell resolution.

While studying mechanisms of protein aggregation, we became interested in another insoluble structure, the stress granule (SG), which is a complex of RNA and proteins that accumulates inside the cytoplasm of cells subjected to environmental stress. By focusing on this granular structure, our lab and Dr. Hojoong Kwak’s lab at Cornell University recently developed a novel method, called RG RNA-seq, for characterizing mRNA species trapped in insoluble SGs. Using this new method, we revealed that ER stress, heat shock and arsenic toxicity, which provoke distinct transcriptional responses, induce a conserved response in stress-induced RNA granulation. Interestingly, we found that proto-oncogenic transcripts are selectively recruited to insoluble SGs after all three types of stress. Therefore, SG targeting seems to be a novel layer of stress-dependent gene regulation, which is universally important for stress adaptation but was formerly unappreciated. This story was recently published in Molecular Cell as a cover story article (Namkoong et al. Mol Cell 70, 175).

After the publication of this paper, this new method was soon applied to various research projects. For instance, Dr. Kwak’s lab combined RG RNA-seq with a novel method of measuring the length of poly-A tails (TED-seq) and revealed that SG-targeted mRNAs have a dramatically reduced poly-A tail length. These results suggested that SG targeting is associated with decreased protein expression (Woo et al. Cell Rep 24, 3630). Another collaboration with Dr. Dan Klionsky’s group at the UM Life Science Institute revealed that Dhh1, a stress granule protein, controls protein expression of autophagy-regulating proteins during nutrient starvation (Liu et al. PLoS Biol. 17, e3000219). In collaboration with Dr. Samie Jaffrey’s group at the Weill-Cornell Medical College, we also utilized the RG isolation technique to support that m6A modification of mRNAs is an important driving factor for RNA sequestration in SGs (Ries et al. Nature 571, 424).

Finally, stress insults induce heterogeneous responses in individual cells, which can lead to variations in cell fate determination. However, stress responses were typically measured in bulk RNA or proteins, so cell-specific stress response has not been examined. To overcome this limitation, we collaborated with Dr. Hyun-Min Kang’s lab in the Department of Biostatistics at the University of Michigan, an expert in developing new computational tools for analyzing single cell RNA-seq data. Using the single cell RNA-seq technique, we found that, upon DNA damage, cells undergoing different fates have distinct transcriptomic landscapes that affect their cell fate response. Although DNA damage response genes were thought to be uniformly induced after DNA damage, our data indicated that many of them were actually expressed in a specific subset of cells having a specific cell fate. These findings provide valuable insights into understanding chemotherapy responses of cancer cells, such as fractional killing and chemoresistance development (Park et al. bioRxiv 10.1101/737130).

The same single cell RNA-seq technique was applied to understand hepatocyte responses to hypernutrition and obesity. Through this, we showed that all hepatocytes, regardless of their metabolic zonation and fat accumulation profiles, undergo substantial transcriptome alteration upon HFD; however, the alteration patterns were highly heterogeneous across the hepatocyte population with zonation-dependent and -independent effects. We also isolated transcriptome features that can explain how different hepatocytes have different rates of lipid droplet accumulation in the liver. This dataset provided a unique and useful resource for understanding hepatocellular alteration during non-alcoholic fatty liver disease (NAFLD) at single cell level (Park et al. bioRxiv 10.1101/2020.04.16.045260).

Systematic Characterization of Stress-Induced RNA Granulation

We devised a novel method for characterizing mRNA species sequestered in insoluble RNP granules in normal and stressed cells. Using the method, we showed that endoplasmic reticulum (ER) stress targets only a small subset of translationally suppressed mRNAs into the insoluble RNP granule fraction (RG). This subset, characterized by extended length and adenylate-uridylate (AU)-rich motifs, is highly enriched with genes critical for cell survival and proliferation. This pattern of RG targeting was conserved for two other stress types, heat shock and arsenite toxicity, which induce distinct responses in the total cytoplasmic transcriptome. Nevertheless, stress-specific RG-targeting motifs, such as guanylate-cytidylate (GC)-rich motifs in heat shock, were also identified. Previously underappreciated, transcriptome profiling in the RG may contribute to understanding human diseases associated with RNP dysfunction, such as cancer and neurodegeneration. The image and text are from Mol Cell 70, 175-187.

Previous Research Statements

As of Fall 2011

Previously, the PI investigated genetic programs governing diverse animal physiologies using Drosophila and mice as model organisms. Specifically, he focused on several key signaling pathways that control growth, aging, differentiation, innate immunity, inflammation, apoptosis and cell polarity. For his Ph.D. thesis, he studied the function of p53 and LKB1, two tumor suppressors frequently mutated in human cancers. Using p53-null flies, one of the first models lacking all p53 function, he confirmed the role of p53 in DNA damage-induced apoptosis and maintenance of genomic stability (Lee et al. FEBS lett 550, 5). In addition, through fly genetic screening, he found that JNK mediates LKB1-induced apoptosis (Lee et al. Cell Death Differ 13, 1110). Subsequent studies led him to make a more striking finding that AMPK, a downstream kinase of LKB1, is mediating energy-dependent regulation of cell shape. This work was published in Nature (Lee et al. Nature 447, 1017).

As a postdoc in Dr. Karin’s lab at UC San Diego, he focused on Sestrins, novel stress-inducible molecules regulated by p53. Utilizing his expertise in Drosophila and p53/AMPK/TOR signaling, he was able to reveal the novel role for Sestrin as a feedback regulator of TOR signaling, which attenuates diverse age- and obesity-associated pathologies such as cancerous cell growth, fat accumulation, muscle degeneration and cardiac malfunction. He also suggested that the pathologies partially result from defective ATG1-mediated autophagy and diminished clearance of dysfunctional mitochondria, protein aggregates, and lipids. This work was published in Science as the cover story article (Lee et al. Science 327, 1223). In parallel with the Sestrin project, he was involved in another project that investigates the relationship between obesity and liver cancer, and found that inflammatory cytokine signalings are critical for obesity promotion of liver pathologies, such as hepatosteatosis, steatohepatitis and hepatocellular carcinoma (Park et al. Cell 140, 197). In subsequent studies, he found that mammalian Sestrin 2 is functioning to attenuate the obesity-induced metabolic derangements in mouse liver.

As an independent lab, we will continue focusing on the role of Sestrins in suppressing diverse pathologies that are associated with obesity and aging, using Sestrins-KO and transgenic mice and mouse models of cancer, metabolic diseases, neurodegeneration, cardiac arrhythmia and muscle degeneration. Considering that Sestrins are stress-inducible proteins, these studies may reveal a potential role of Sestrin in mediating hormesis, a paradoxical beneficial effects of low-level stresses.

At the same time, using phospho-proteomics and genome-wide RNAi screening in Drosophila cells, we will identify new genetic components that mediate ATG1-dependent control of autophagy and autophagic removal of damaged mitochondria, which are critical for preventing aging and associated pathologies. Then, using Drosophila genetics, we will characterize the biological roles of newly isolated genetic components. Following these foundation-building experiments, we will embark on long-term mouse experiments on the molecules and related hypotheses. By utilizing both Drosophila and mouse systems, we will be able to conduct the two-pronged approaches for each individual research project, and this dual strategy will increase the effectiveness of our research program and allow us to decipher the fundamental genetic mechanisms of growth and aging that are encoded in our genome.